Second primary malignancies induced by radioactive iodine treatment of differentiated thyroid carcinoma - a critical review and evaluation of the existing evidence.
Differentiated thyroid carcinoma
Dose–response relationship
Effect of dose on second primary malignancy risk
Hematologic malignancy
Radioiodine therapy
Second primary malignancy
Journal
European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
received:
10
02
2022
accepted:
11
03
2022
pubmed:
24
3
2022
medline:
7
7
2022
entrez:
23
3
2022
Statut:
ppublish
Résumé
Concern is growing about long-term side effects of differentiated thyroid cancer treatment, most notably radioactive iodine (RAI) therapy. However, published studies on the subject have had heterogeneous cohorts and conflicting results. This review seeks to provide an updated evaluation of published evidence, and to elucidate the risk of second primary malignancies (SPMs), especially secondary hematologic malignancies (SHMs), attributable to RAI therapy. An extensive literature search was performed in Ovid MEDLINE, Ovid MEDLINE and In-Process & Other Non-Indexed Citations, Ovid MEDLINE Epub Ahead of Print, Cochrane Central Register of Controlled Trials (CENTRAL) and PubMed. Studies regarding RAI-induced SPMs or a dose-response relationship between RAI therapy and SPMs were identified, 10 of which were eligible for the analysis. We evaluated risk of bias in each study and judged quality of evidence (QOE) across all studies using the Grading of Recommendations, Assessment, Development and Evaluations approach. For the outcome "SPM", the relative effect (relative risk, hazard ratio, or odds ratio) of RAI vs. no RAI ranged from 1.14 to 1.84 across studies, but most results were not statistically significant. For the outcome "SHM", reported relative effects ranged from 1.30 to 2.50, with 2/3 of the studies presenting statistically significant results. In 7/8 of the studies, increased risk for SPM was shown with increasing cumulative RAI activity. QOE was "very low" regarding SPM after RAI and regarding a dose-response relationship, and "low" for SHM after RAI. Based on low quality evidence, an excess risk for the development of SPM cannot be excluded but is expected to be small.
Identifiants
pubmed: 35320386
doi: 10.1007/s00259-022-05762-4
pii: 10.1007/s00259-022-05762-4
pmc: PMC9250458
doi:
Substances chimiques
Iodine Radioisotopes
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
3247-3256Informations de copyright
© 2022. The Author(s).
Références
Thyroid. 2007 Dec;17(12):1277-88
pubmed: 18020916
Nuklearmedizin. 2019 Mar;58(2):86-92
pubmed: 30917397
EJNMMI Phys. 2017 Nov 21;4(1):27
pubmed: 29164483
J Clin Endocrinol Metab. 2008 Feb;93(2):504-15
pubmed: 18029468
Eur Thyroid J. 2022 Jan 01;11(1):
pubmed: 34981741
Br J Cancer. 1991 Jul;64(1):159-63
pubmed: 1854616
Thyroid. 2019 Jan;29(1):7-26
pubmed: 30484394
Radiat Res. 1994 Feb;137(2 Suppl):S68-97
pubmed: 8127953
Int J Clin Oncol. 2016 Apr;21(2):231-239
pubmed: 26410770
Cancer Treat Rev. 2015 Dec;41(10):925-34
pubmed: 26421813
N Engl J Med. 2014 Dec 25;371(26):2477-87
pubmed: 25426838
N Engl J Med. 2016 Aug 18;375(7):614-7
pubmed: 27532827
Thyroid. 2016 Aug;26(8):1110-6
pubmed: 27302111
Cancer Causes Control. 2018 May;29(4-5):465-473
pubmed: 29623496
Clin Endocrinol (Oxf). 2015 Jul;83(1):117-23
pubmed: 25115234
Thyroid. 2017 Jul;27(7):944-952
pubmed: 28446057
Ann Surg Oncol. 2007 Feb;14(2):730-8
pubmed: 17103065
Thyroid. 2018 Dec;28(12):1662-1673
pubmed: 30370820
J Natl Cancer Inst. 2015 Nov 03;108(2):
pubmed: 26538627
Endocr Relat Cancer. 2016 Apr;23(4):313-22
pubmed: 26917552
Eur J Nucl Med Mol Imaging. 2008 Jul;35(7):1405-12
pubmed: 18491092
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
Pediatr Clin North Am. 2020 Dec;67(6):1135-1154
pubmed: 33131538
Surgery. 2012 Jun;151(6):844-50
pubmed: 22341041
J Clin Endocrinol Metab. 2015 Apr;100(4):1529-36
pubmed: 25642591
BMJ. 1998 Mar 28;316(7136):989-91
pubmed: 9550961
Dtsch Arztebl Int. 2009 Nov;106(48):795-800
pubmed: 20038982
Eur J Cancer. 2021 Mar;145:71-80
pubmed: 33423008
Eur J Nucl Med Mol Imaging. 2008 Oct;35(10):1941-59
pubmed: 18670773
Nucl Med Commun. 2014 Aug;35(8):808-17
pubmed: 24751702
BMJ. 2016 Oct 12;355:i4919
pubmed: 27733354
J Nucl Med. 1995 Jan;36(1):21-7
pubmed: 7799075
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Br J Cancer. 2003 Nov 3;89(9):1638-44
pubmed: 14583762
Thyroid. 2017 Aug;27(8):1068-1076
pubmed: 28614983
Stat Med. 1998 Jun 30;17(12):1341-55
pubmed: 9682324
Clin Nucl Med. 2011 Apr;36(4):277-82
pubmed: 21368600
J Clin Oncol. 2018 Jun 20;36(18):1831-1839
pubmed: 29252123
Thyroid. 2009 May;19(5):451-7
pubmed: 19281429
J Clin Oncol. 2017 May 10;35(14):1598-1605
pubmed: 28068180
Thyroid. 2016 Jan;26(1):1-133
pubmed: 26462967
Thyroid. 2019 Apr;29(4):461-470
pubmed: 30900516
Eur J Nucl Med Mol Imaging. 2020 Jan;47(1):78-83
pubmed: 31616967
Nat Genet. 2012 Nov;44(11):1179-81
pubmed: 23001125
J Chronic Dis. 1987;40 Suppl 2:45S-57S
pubmed: 3312274
Br J Cancer. 1997;75(5):734-9
pubmed: 9043033
Thyroid. 2021 Jul;31(7):1009-1019
pubmed: 33789450
J Radiol Prot. 2009 Jun;29(2A):A43-59
pubmed: 19454804